Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial. J of Skin. 2024;8(6):s488. doi:10.25251/skin.8.supp.488